###begin article-title 0
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin-Cyclophosphamide Regimen
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 287 311 287 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tumor protein p53 (TP53)</italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 673 677 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 241 248 <span type="species:ncbi:9606">patient</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
In breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification of markers that could predict the response to a particular regimen would thus be critically important for patient care. In cell lines or animal models, tumor protein p53 (TP53) plays a critical role in modulating the response to genotoxic drugs. TP53 is activated in response to DNA damage and triggers either apoptosis or cell-cycle arrest, which have opposite effects on cell fate. Yet, studies linking TP53 status and chemotherapy response have so far failed to unambiguously establish this paradigm in patients. Breast cancers with a TP53 mutation were repeatedly shown to have a poor outcome, but whether this reflects poor response to treatment or greater intrinsic aggressiveness of the tumor is unknown.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 506 510 506 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 646 650 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 689 693 689 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 885 889 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1010 1014 1010 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1043 1062 1043 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDC20, TTK, CDKN2A,</italic>
###xml 1086 1092 1086 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROM1,</italic>
###xml 1183 1187 1183 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1248 1252 1248 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1342 1346 1342 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1503 1507 1503 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 545 550 <span type="species:ncbi:4932">yeast</span>
###xml 1206 1214 <span type="species:ncbi:9606">patients</span>
###xml 1317 1325 <span type="species:ncbi:9606">patients</span>
In this study we analyzed 80 noninflammatory breast cancers treated by frontline (neoadjuvant) chemotherapy. Tumor diagnoses were performed on pretreatment biopsies, and the patients then received six cycles of a dose-dense regimen of 75 mg/m2 epirubicin and 1,200 mg/m2 cyclophosphamide, given every 14 days. After completion of chemotherapy, all patients underwent mastectomies, thus allowing for a reliable assessment of chemotherapy response. The pretreatment biopsy samples were used to determine the TP53 status through a highly efficient yeast functional assay and to perform RNA profiling. All 15 complete responses occurred among the 28 TP53-mutant tumors. Furthermore, among the TP53-mutant tumors, nine out of ten of the highly aggressive basal subtypes (defined by basal cytokeratin [KRT] immunohistochemical staining) experienced complete pathological responses, and only TP53 status and basal subtype were independent predictors of a complete response. Expression analysis identified many mutant TP53-associated genes, including CDC20, TTK, CDKN2A, and the stem cell gene PROM1, but failed to identify a transcriptional profile associated with complete responses among TP53 mutant tumors. In patients with unresponsive tumors, mutant TP53 status predicted significantly shorter overall survival. The 15 patients with responsive TP53-mutant tumors, however, had a favorable outcome, suggesting that this chemotherapy regimen can overcome the poor prognosis generally associated with mutant TP53 status.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53,</italic>
###xml 500 508 <span type="species:ncbi:9606">patients</span>
This study demonstrates that, in noninflammatory breast cancers, TP53 status is a key predictive factor for response to this dose-dense epirubicin-cyclophosphamide regimen and further suggests that the basal subtype is exquisitely sensitive to this association. Given the well-established predictive value of complete responses for long-term survival and the poor prognosis of basal and TP53-mutant tumors treated with other regimens, this chemotherapy could be particularly suited for breast cancer patients with a mutant TP53, particularly those with basal features.
###end p 6
###begin p 7
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Hugues de The and colleagues report thatTP53 status is a predictive factor for responsiveness in breast cancers to a dose-dense epirubicin-cyclophosphamide chemotherapy regimen, and suggests that this regimen might be well suited for patientsTP53 mutant tumors.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 964 968 964 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1119 1123 1119 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 4 9 <span type="species:ncbi:9606">woman</span>
###xml 284 289 <span type="species:ncbi:9606">human</span>
###xml 637 644 <span type="species:ncbi:9606">patient</span>
One woman in eight will develop breast cancer during her life. As with other cancers, breast cancer arises when cells accumulate genetic changes (mutations) that allow them to grow uncontrollably and to move around the body. These altered cells are called malignant cells. The normal human breast contains several types of cell, any of which can become malignant. In addition, there is more than one route to malignancy-different sets of genes can be mutated. As a result, breast cancer is a heterogeneous disease that cannot be cured with a single type of treatment. Ideally, oncologists would like to know before they start treating a patient which therapeutic approach is going to be successful for that individual. Recently, researchers have begun to identify molecular changes that might eventually allow oncologists to make such rational treatment decisions. For example, laboratory studies in cell lines or animals indicate that the status of a gene called TP53 determines the chemotherapy agents (drugs that preferentially kill rapidly dividing cancer cells) to which cells respond. p53, the protein encoded by TP53, is a tumor suppressor. That is, in normal cells it prevents unregulated growth by controlling the expression of proteins involved in cell division and cell death. Consequently, p53 is often inactivated during cancer development.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 411 415 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 583 588 <span type="species:ncbi:9606">women</span>
Although laboratory studies have linked TP53 status to chemotherapy responses, little is known about this relationship in human breast cancers. The clinical studies that have investigated whether TP53 status affects chemotherapy responses have generally found that patients whose tumors contain mutant TP53 have a poorer response to therapy and/or a shorter survival time than those whose tumors contain normal TP53. In this study, the researchers have asked whether TP53 status affects tumor responses to a dose-intense chemotherapy regimen (frequent, high doses of drugs) given to women with advanced noninflammatory breast cancer before surgery. This type of treatment is called neoadjuvant chemotherapy and is used to shrink tumors before surgery.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 356 360 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 825 829 825 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 971 975 971 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1038 1042 1038 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1081 1085 1081 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1248 1252 1248 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 55 60 <span type="species:ncbi:9606">women</span>
###xml 171 176 <span type="species:ncbi:9606">woman</span>
###xml 877 885 <span type="species:ncbi:9606">Patients</span>
The researchers collected breast tumor samples from 80 women before starting six fortnightly cycles of chemotherapy with epirubicin and cyclophosphamide. After this, each woman had her affected breast removed and examined to see whether the chemotherapy had killed the tumor cells. The researchers determined which original tumor samples contained mutated TP53 and used a technique called microarray expression profiling to document gene expression patterns in them. Overall, 28 tumors contained mutated TP53. Strikingly, all 15 tumors that responded completely to neoadjuvant chemotherapy (no tumor cells detectable in the breast tissue after chemotherapy) contained mutated TP53. Nine of these responsive tumors were basal-cell-like breast tumors, a particularly aggressive type of breast cancer; only one basal-cell-like, TP53-mutated tumor did not respond to chemotherapy. Patients whose tumors were unresponsive to the neoadjuvant chemotherapy but contained mutated TP53 tended to die sooner than those whose tumors contained normal TP53 or those with chemotherapy-responsive TP53-mutated tumors. Finally, expression profiling identified changes in the expression of many p53-regulated genes, but did not identify an expression profile in the TP53-mutated tumors unique to those that responded to chemotherapy.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 512 516 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1022 1026 1022 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 997 1005 <span type="species:ncbi:9606">patients</span>
These findings indicate that noninflammatory breast tumors containing mutant TP53-in particular, basal-cell-like tumors-are very sensitive to dose-dense epirubicin and cyclophosphamide chemotherapy. Intensive regimens of this type have rarely been used in previous studies, which might explain the apparent contradiction between these results and the generally poor response to chemotherapy of TP53-mutated breast tumors. More tumors now need to be examined to confirm the association between complete response, TP53 status and basal-cell-like tumors. In addition, although complete tumor responses generally predict good overall survival, longer survival studies than those reported here are needed to show that the tumor response to this particular neoadjuvant chemotherapy regimen translates into improved overall survival. If the present results can be confirmed and extended, dose-dense neoadjuvant chemotherapy with epirubicin and cyclophosphamide could considerably improve the outlook for patients with aggressive TP53-mutant, basal-cell-like breast tumors.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
###xml 42 49 <span type="species:ncbi:9606">patient</span>
The US National Cancer Institute provides patient and physician information on  and general information on
###end p 19
###begin p 20
###xml 26 33 <span type="species:ncbi:9606">patient</span>
Cancer Research UK offers patient information on  and
###end p 20
###begin p 21
The  encyclopedia has pages on breast cancer
###end p 21
###begin p 22
Emory University's  discusses the biology of cancer, including the role of tumor suppressor proteins
###end p 22
###begin p 23
 has pages on p53 (note that Wikipedia is a free online encyclopedia that anyone can edit)
###end p 23
###begin title 24
Introduction
###end title 24
###begin p 25
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b001">1</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b005">5</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b006">6</xref>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b008">8</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Breast cancers are a heterogeneous group of tumors. While most breast cancer patients receive chemotherapy, less than 20% of those receiving neoadjuvant treatment will reach complete pathological response (disappearance of invasive tumor cells in pathological tissue samples), which strongly predicts long-term survival [1-5]. Predictive molecular determinants for conventionally dosed chemotherapy responses are only emerging [6-8], and very little is known regarding prediction of response to dose-dense treatments.
###end p 25
###begin p 26
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tumor protein p53 (TP53),</italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PUMA</italic>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAX)</italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(SFN</italic>
###xml 292 299 292 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A)</italic>
###xml 332 336 332 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b009">9</xref>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b010">10</xref>
Tumor protein p53 (TP53), the prototypic tumor suppressor gene, is a master gene of stress response that plays a key role in cancer development. TP53 is a transcription factor that controls the expression of many genes implicated in apoptosis (PUMA and BAX) or cell-cycle regulation (SFN and CDKN1A). In animal or cell-line models, TP53 was shown to play a critical role in the response to DNA damage induced by a number of anticancer therapies [9]. In fact, TP53 inactivation may promote an exquisite sensitivity to some agents, but resistance to others [10].
###end p 26
###begin p 27
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 613 617 613 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b011">11</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b012">12</xref>
###xml 714 718 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 817 821 817 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b013">13</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b017">17</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 700 708 <span type="species:ncbi:9606">patients</span>
The role of TP53 status in determining the response to a given cytotoxic treatment in patients is largely unsettled, in part because of technical difficulties in establishing TP53 status in the clinical setting, and because most studies analyzed survival rather than initial tumor response. While tumor disappearance is a direct and unambiguous measure of chemotherapy efficiency, survival is a composite endpoint, which incorporates not only the efficiencies of the different treatments, but also the intrinsic aggressiveness of the disease. In hematological malignancies, several studies have found that mutant TP53 status is associated with treatment failure [11,12]. Similarly, in breast cancer, patients with TP53-mutant tumors often have poor responses to therapy and/or shorter survival than those with normal TP53 [13-17].
###end p 27
###begin p 28
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b018">18</xref>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
Here, we have used a highly sensitive functional TP53 assay, which not only determines the functional impact of TP53 mutations, but also explores other dysfunctions, such as splicing defects [18], to analyze a group of breast cancer patients treated with a neoadjuvant dose-intense chemotherapy regimen.
###end p 28
###begin title 29
Methods
###end title 29
###begin title 30
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 30
###begin p 31
###xml 248 256 248 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040090-t001">Tables 1</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">S1</xref>
###xml 648 649 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 675 676 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b019">19</xref>
###xml 950 954 950 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1099 1107 1099 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 1221 1225 1221 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1254 1262 1254 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 1346 1348 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b020">20</xref>
###xml 1373 1381 1373 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040090-t001">Tables 1</xref>
###xml 1386 1388 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">S1</xref>
###xml 1747 1749 1747 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b020">20</xref>
###xml 2012 2014 2012 2014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b021">21</xref>
###xml 2226 2234 2226 2234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 2699 2701 2699 2701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b022">22</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 862 870 <span type="species:ncbi:9606">patients</span>
###xml 1040 1048 <span type="species:ncbi:9606">patients</span>
###xml 1081 1088 <span type="species:ncbi:9606">patient</span>
###xml 1175 1182 <span type="species:ncbi:9606">patient</span>
###xml 1208 1215 <span type="species:ncbi:9606">patient</span>
###xml 1240 1247 <span type="species:ncbi:9606">patient</span>
###xml 1301 1309 <span type="species:ncbi:9606">Patients</span>
###xml 1363 1371 <span type="species:ncbi:9606">patients</span>
###xml 1558 1566 <span type="species:ncbi:9606">patients</span>
###xml 1628 1636 <span type="species:ncbi:9606">patients</span>
###xml 1672 1680 <span type="species:ncbi:9606">patients</span>
###xml 2021 2029 <span type="species:ncbi:9606">patients</span>
###xml 2201 2209 <span type="species:ncbi:9606">patients</span>
###xml 2348 2356 <span type="species:ncbi:9606">patients</span>
Two hundred and six patients with inflammatory and noninflammatory breast cancers treated at a single institution from 1997 to 2003 underwent open incisional biopsy (0.5-3 cm in size) followed by first-line chemotherapy and consented to the study (Tables 1 and S1). One hundred and twenty six patients were not included for the following reasons: inflammatory breast cancer (78 tumors), frozen tumor tissue absent or unsuitable for RNA analysis (29 tumors), absence of further mastectomy (16 cases) or undefined response (three cases: patients P80, P81, P83; see below). The 80 remaining patients were treated with exactly the same regimen (75 mg/m2 epirubicin and 1,200 mg/m2 cyclophosphamide, delivered every 14 d [19] with granulocyte-colony stimulating factor support in case of febrile neutropenia) and had unambiguous pathological response data. Of the 80 patients, 35 were included in the microarray profiling analysis, as were two additional TP53-mutant tumor samples previously excluded from the treatment response analysis as the patients had received another treatment (patient P81) (see Table S1) or had an initial biopsy that may have removed most of the tumor (patient P80). A third additional patient with TP53 mutant tumor (patient P83) (Table S1) was included for validation studies. Patients were staged IIb, IIIa, IIIb, or IV [20], except four patients (Tables 1 and S1) with a T2N0M0 (stage IIa) disease who had documented tumor doubling time of less than 6 mo (two cases) or who had tumors over 3 cm in size (two cases). The group of 80 patients included in the study was not different from the 48 excluded patients with noninflammatory breast cancer patients in terms of age and TNM Classification of Malignant Tumors stage [20] with, respectively, median age 48 y (24-76 y) and 52 y (29-74 y) and TNM: T1, 0% and 5%; T2, 14% and 19%; T3, 45% and 43%; T4, 41% and 33%; N+, 75% and 71%; and M+, 19% and 13%. Tumors were graded according to the modified Scarff, Bloom, and Richardson system [21]. All patients were screened for metastasis at diagnosis with at least chest x-ray, liver ultrasound, or thoraco-abdomino-pelvic CT scan and bone scintigram. At the time of diagnosis 11 patients had metastases (Table S1). After completion of the planned six cycles of primary chemotherapy-thus approximately 3 mo after diagnosis-the patients underwent mastectomy and axillary lymph node dissection. Pathologically assessed complete response was defined by the complete disappearance of invasive tumor cells in the mastectomy specimen and in the lymph nodes or a single microscopic invasive focus (P4) or residual breast in situ carcinoma (P42, P46, and P69), as previously described [22].
###end p 31
###begin title 32
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
TP53 Typing
###end title 32
###begin p 33
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b023">23</xref>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b024">24</xref>
###xml 553 561 553 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st002">Table S2</xref>
###xml 857 865 857 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st002">Table S2</xref>
###xml 34 39 <span type="species:ncbi:4932">yeast</span>
###xml 101 106 <span type="species:ncbi:4932">yeast</span>
###xml 231 236 <span type="species:ncbi:4932">yeast</span>
###xml 450 455 <span type="species:ncbi:4932">yeast</span>
TP53 status was determined by the yeast functional assay, in which mutant TP53 transcripts yield red yeast colonies and wild-type transcripts yield white ones [23]. Tumors were considered TP53 mutant when: (i) more than 15% of the yeast colonies were red, (ii) analysis using the split versions of the test could identify the defect in the 5' or 3' part of the gene, confirming the initial determination [24], and (iii) sequence analysis from mutant yeast colonies could identify an unambiguous genetic defect (mutation, deletion, or splicing defects) (Table S2). All tumors with more than 15% red colonies fulfilled these three criteria. Note that the four tumors with low percentage of mutant colonies (15%-25%) all exhibited stop or frame-shift mutations, defects known to be associated with nonsense mediated RNA decay, resulting in low mRNA abundance (Table S2). Prediction of dominant negative activity was performed using IARC software ().
###end p 33
###begin title 34
RNA Analysis
###end title 34
###begin p 35
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b022">22</xref>
###xml 220 228 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 320 326 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
RNA was prepared as previously [22], yielding 2-83 mug (mean 17 mug) of RNA. Its quality was verified by Agilent bioanalyzer (), and Affymetrix arrays () were performed after a single or a double round of amplification (Table S1). RT-PCR was performed using Gene Expression Assays (Applied Biosystems, ), except for the CDKN2A locus for which we designed specific primers (available upon request).
###end p 35
###begin title 36
Immunohistochemistry
###end title 36
###begin p 37
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b025">25</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b026">26</xref>
Immunohistochemical analyses were carried out on paraffin sections using antibodies directed against estrogen receptor 1 (ESR1) (clone 6F11) (Novocastra, ), keratin 5/6 (KRT5/6) (clone D5/16 B4) (DakoCytomation, ), keratin 17 (KRT17) (clone E3) (DakoCytomation), cyclin-dependent kinase inhibitor 2A (CDKN2A [p16] (clone E6H4) (DakoCytomation), and on frozen sections using antibodies directed against prominin 1 (PROM1 [CD133/1]) (clone AC133) (Miltenyi Biotec, ). Basal KRT (5/6 or 17) or PROM1 were scored positive if strong cytoplasmic staining was observed in any invasive carcinoma cells [25,26]. For all other antibodies, there was either no staining (negative cases) or a positive staining in more than 10% of tumor cells (positive cases) either in nucleus (ESR1, CDKN2A) and/or in cytoplasm (CDKN2A).
###end p 37
###begin title 38
Statistics and Bioinformatics
###end title 38
###begin p 39
###xml 56 64 56 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 659 663 659 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">affy</italic>
###xml 698 699 698 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1625 1626 1625 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2033 2034 2033 2034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2154 2155 2154 2155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2167 2168 2167 2168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2173 2176 2173 2176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">med</sub>
###xml 2185 2186 2185 2186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2274 2275 2274 2275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2295 2296 2295 2296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2433 2434 2433 2434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Microarray data analysis was based on 37 tumor samples (Table S1): 29 (set S1) processed using the one-cycle target labeling protocol (Affymetrix), and eight (set S2) processed using the two-cycle target-labeling protocol. RT-PCR data analysis was based on 82 tumor samples: 37 from the microarray series (S1 + S2) and 45 new samples (set S3). Except as indicated, all transcriptome analysis was carried out using either an assortment of R-system software (version 1.9.0) packages including those of Bioconductor (version 1.1.1) () or original R code. Raw feature data from Affymetrix HG-U133A GeneChip microarrays were normalized using RMA method (R package affy version 1.4.32), which yielded log2 intensity expression summary values for each of the 22,283 probe sets. Each set (S1 and S2) was normalized independently. Individual feature data from set S1 and S2 were normalized in batches along with an additional 17 (one-cycle) and 19 (two-cycle) samples unrelated to this study, respectively. Probe sets corresponding to control genes or having an "x" annotation were masked, leaving 19,987 probe sets for further analyses. Clustering analysis of the samples was performed using DNA-Chip Analyzer software (dChip version 1.3, ) with (1 - Pearson correlation coefficient) as distance metric and Centroid linkage. The RMA normalized data of 37 samples (S1 + S2) were used in this analysis, based on a subset of 990 probe sets. These 990 probe sets were selected using only set S1 based on the two following criteria: (i) a robust coefficient of variation (rCV) superior to the 95th rCV percentile and below 10, and (ii) a p-value of a variance test (see below) less than 0.01. For each probe set, rCV was calculated by first eliminating the highest and lowest expression values for that probe set out of all of the samples. From the remaining samples we divided the standard deviation of the expression values by the mean expression values. This yielded an rCV value for each probe set. The variance calculated for each probe set P (variance across all samples) was compared to the median variance from all 19,987 probe sets. The statistic used was ([n - 1] x Var(P)/Varmed), where n refers to the number of samples. This statistic was compared to a percentile of the Chi2 distribution with (n - 1) degrees of freedom (this criterion is used in the BRB Array Tools filtering tool, described in the user's manual []) and yielded a p-value for each probe set.
###end p 39
###begin p 40
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 533 536 533 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(n)</italic>
###xml 552 553 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 588 589 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 738 739 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 788 789 788 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 806 807 806 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 843 844 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 968 978 968 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-sd001">Dataset S1</xref>
We performed all univariate t- and F-tests using BRB Array Tools (version 3.0 b2) on the RMA normalized data for the 19,787 probe sets. We designated a significance level of each univariate test of p < 0.001 (except when otherwise indicated). To evaluate the number of false positives (due to multiple testing), we used a Monte Carlo approach (implemented in BRB comparison tool) based on 1,000 random sample label permutations. This method calculates the false discovery rate (with a probability of 90%), on the basis of the number (n) of probe sets (n first probe sets ordered by their p-value from the univariate test) identified where the false discovery is relative to the chosen level of significance for the univariate test (e.g., p = 0.001). This method also evaluates the number n' of probe sets (n' first probe sets ordered by their p-value from the univariate test) for which the number of false discoveries is less than 10 (with a probability of 90%). See Dataset S1 for the statistics related to the definitions of the genes associated with the C1, C2, and C3 groups.
###end p 40
###begin p 41
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 347 355 347 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PROM1),</italic>
###xml 368 376 368 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TMSNB),</italic>
###xml 389 396 389 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(KRT7),</italic>
###xml 407 414 407 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(RIS1),</italic>
###xml 427 436 427 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(PHLDA2),</italic>
###xml 446 453 446 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(MAFF),</italic>
###xml 464 470 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ADM),</italic>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TTK),</italic>
###xml 500 508 500 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CDC20),</italic>
###xml 523 531 523 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CDKN2A)</italic>
###xml 543 553 543 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">[FLJ10901]</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 730 736 730 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1032 1034 1032 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s,</italic>
###xml 1039 1043 1039 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene</sub>
###xml 1043 1046 1043 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(s)</italic>
###xml 1052 1056 1052 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene</sub>
###xml 1057 1058 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 1076 1080 1076 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene</sub>
###xml 1110 1114 1110 1114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene</sub>
###xml 1114 1117 1114 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(s)</italic>
###xml 1122 1126 1122 1126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene</sub>
###xml 1126 1129 1126 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(s)</italic>
###xml 1134 1144 1134 1144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">calibrator</sub>
###xml 1144 1148 1144 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(s),</italic>
###xml 1164 1167 1164 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBP</italic>
###xml 1218 1228 1218 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-sd001">Dataset S1</xref>
Based on the t-tests of TP53 status described above, we sorted the 1,599 obtained probe sets by fold change (ratio of the geometric mean intensity in the 17 TP53 mutant samples versus the geometric mean intensity in the 12 TP53 wild-type samples). We then selected the ten well-characterized probe sets having the highest fold change: 204304_s_at (PROM1), 205347_s_at (TMSNB), 209016_s_at (KRT7), 213338_at (RIS1), 209803_s_at (PHLDA2), 36711_at (MAFF), 202912_at (ADM), 204822_at (TTK), 202870_s_at (CDC20), and 207039_at (CDKN2A) (219010_at [FLJ10901] was filtered, as it is not well characterized). We also selected ESR1 (second highest inverse fold change). This yielded 12 gene transcripts for further study with RT-PCR (for CDKN2A we used two targets: p14 and p16). Due to a lack of sample RNA, only 948 data points (Ct [gene, sample]) from a total of 984 possible data points (12 genes x 82 samples) were available. These Ct values were normalized to yield ddCt values, based on the following calculation: for a given sample s, ddCtgene(s) = dCtgene(s) - (Median of dCtgene across all samples), with dCtgene(s) = Ctgene(s) - Ctcalibrator(s), using the gene TBP (TATA-binding protein) as the reference gene. See Dataset S1 for the statistics associated with the RT-PCR data of these 12 genes.
###end p 41
###begin title 42
Statistical Methods for the Analysis of the Clinical Data
###end title 42
###begin p 43
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 552 553 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
The association between treatment response and potential prognostic variables (age, tumor grade, cytoplasmic staining of CDKN2A, presence of KRT5/6 or 17, ERBB2 mRNA expression, ESR1 protein expression, T stage from TNM classification, and TP53 mutation status) was tested using Fisher's exact test. Because the age of the patients represents a continuous variable, patients were divided into two classes using a cutoff at age 50. Stratified association analyses were performed using the Mantel-Haenszel test. Kaplan-Meier survival curves and log-rank p-values were calculated on the basis of either event-free survival (considering local relapse or distant metastasis as an event) in the population of patients that were free of metastasis at diagnosis or overall survival on the complete population.
###end p 43
###begin title 44
Results
###end title 44
###begin title 45
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
All Complete Responses to a Dose-Dense Chemotherapy Harbor TP53 Mutations
###end title 45
###begin p 46
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b022">22</xref>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 350 358 350 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 706 714 706 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st002">Table S2</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
We had previously observed, in 49 of our 206 patients, that complete responses were preferentially achieved when tumors bore TP53 mutations [22]. Analysis of the consecutive cohort of 31 patients independently validated this association (p = 0.0003), which became compelling (p = 10-8) when the initial subset and the consecutive cohort were pooled (Figure 1A). Indeed, not a single tumor with a normal TP53 genotype (52 cases) had a complete response, while 15 out of 28 TP53-mutant tumors exhibited complete pathological responses. The predicted effects of the observed mutations and the distribution of R72P polymorphism were not significantly different in tumors with complete or incomplete responses (Table S2).
###end p 46
###begin title 47
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
TP53 Status and Basal Features Are Independent Predictors of Complete Response
###end title 47
###begin p 48
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 135 138 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b007">7</xref>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 480 488 480 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 491 499 491 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040090-t001">Tables 1</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">S1</xref>
###xml 616 620 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 728 737 728 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-sg001">Figure S1</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b027">27</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b029">29</xref>
###xml 946 951 946 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 1033 1037 1033 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1148 1156 1148 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 1202 1206 1202 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1432 1436 1432 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1635 1640 1635 1640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 1701 1709 1701 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 1915 1919 1915 1919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1921 1929 1921 1929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 1988 1992 1988 1992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 2001 2009 2001 2009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 2047 2051 2047 2051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 2387 2391 2387 2391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 2033 2041 <span type="species:ncbi:9606">patients</span>
Many studies have demonstrated that mutant TP53 status is tightly associated with ESR1neg and grade 3 breast cancers. In addition, ESR1pos status was previously associated with chemotherapy resistance [7]. To elucidate the respective contribution of these factors in predicting chemotherapy response, we analyzed the distribution of age, T stage (from TNM classification), tumor grade, TP53 status, staining for ESR1, KRT5/6 or 17, and ERBB2 RNA expression among the 80 patients (Figure 1A; Tables 1 and S1). We also included staining for CDKN2A, a major tumor suppressor whose expression is tightly associated with TP53 status (see below). High transcript and protein levels of CDKN2A are associated with cytoplasmic staining (Figure S1). Therefore we used the cytoplasmic staining pattern as the criteria for deeming a sample CDKN2A positive or negative, as in previous studies [27-29]. No or weakly significant differences in age, T stage, or ERBB2 status were found between complete and incomplete responses. In contrast, grade, TP53 status, ESR1, KRT5/6 or 17, and cytoplasmic CDKN2A (p16) staining were all strongly associated with response (Figure 1A). As there are no complete responses in the TP53 wt group, the estimation of a regression coefficient using the multivariate logistic regression model is impossible, this coefficient being theoretically infinite in such a situation, precluding a multivariate analysis. Yet, TP53 status remained significantly linked to a response in univariate analyses, irrespective of the stratification (age, T stage or tumor grade, KRT5/6 or 17 presence, CDKN2A cytoplasmic staining [p16], ERBB2 mRNA, or ESR1 protein expression) in Mantel-Haenszel tests (Figure 1A). In contrast, with the exception of basal features (KRT5/6 or 17 positivity), all the other individually significant variables significantly associated with complete response prior to stratification for TP53 (Figure 1A) no longer remained significant after stratification for TP53 status (Figure 1A). Moreover, among the patients with TP53 mutations, the 15 tumors with a complete response had sizes and grades (six T2s, five T3s, and four T4s, all grade 3) comparable to the 13 who did not reach a complete response (three T2s, five T3s, and five T4s, all but one grade 3). Altogether, despite the impossibility of a formal multivariate regression analysis, it appears that TP53 and, to a lesser extent, basal features are the only important predictors of complete pathological response.
###end p 48
###begin title 49
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
TP53 Status and Survival
###end title 49
###begin p 50
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 269 277 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 292 300 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 386 394 386 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b001">1</xref>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b005">5</xref>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b013">13</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b014">14</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b030">30</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b031">31</xref>
###xml 696 700 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 792 800 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 857 861 857 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 976 977 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 987 995 987 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 1080 1084 1080 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">Patients</span>
###xml 672 680 <span type="species:ncbi:9606">Patients</span>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
When patients with metastatic disease at diagnosis were excluded from the analysis, most patients with a TP53 mutant tumor had favorable event-free survival, although with the current median follow-up (46 mo, range 3-103 mo), it did not reach statistical significance (Figure 1B, left graph; Table S1). Patients with a basal phenotype or complete responses also had favorable outcomes (Table S1), in line with the well-known association between a complete response and prolonged survival [1-5]. This observation is particularly remarkable, because TP53 mutant tumors have been reported in several studies to have a shorter survival than TP53 wild-type ones [13,14,30,31]. Patients with wild-type TP53 tumors had a relatively favorable overall survival, despite the lack of complete response (Figure 1B, right graph, red curve). Interestingly, patients with TP53-mutant tumors who did not reach complete response had a significantly shorter overall survival than other tumors (p = 0.02) (Figure 1B, right graph, orange curve). Again, absence of complete responses in the wild-type TP53 group precluded a multivariate survival analysis.
###end p 50
###begin title 51
Can Transcriptional Profiling Predict Complete Response?
###end title 51
###begin p 52
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 211 218 211 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="st2">Methods</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b032">32</xref>
###xml 646 654 646 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g002">Figure 2</xref>
###xml 657 666 657 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st003">Tables S3</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st005">S5</xref>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
###xml 626 634 <span type="species:ncbi:9606">patients</span>
In an attempt to better characterize the responsive tumors, we performed expression analyses using microarrays. Of the 83 (three additional TP53 mutant tumor samples were considered for the profiling study, see Methods) breast tumors considered for gene-profiling analysis, 37 had enough high-quality RNA extracted from biopsies before chemotherapy to be analyzed with the arrays, leaving the remaining 46 samples for validation studies. Consistent with previous reports [32], hierarchical cluster analyses of these 37 cancers identified three robust clusters of patients (C1, C2, and C3), as well as the genes defining these patients' clusters (Figure 2A; Tables S3-S5).
###end p 52
###begin p 53
###xml 240 247 240 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="st2">Methods</xref>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 355 363 355 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st006">Table S6</xref>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 590 595 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 658 666 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st007">Table S7</xref>
###xml 705 709 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
To define genes specifically associated with complete responses, we then performed t-tests based on the Affymetrix data on the 28 tumors (nine complete responses and 19 incomplete responses) processed using a single amplification step (see Methods). We identified 77 probe sets using a p-value threshold of 0.001, with a high false discovery rate of 26% (Table S6). Using the same sample population, we identified 1,599 TP53 mutant-associated genes, with a false discovery rate less than 0.1%. As expected, the great majority (54 of 77) of genes associated with complete response were also TP53-associated genes, the others most likely being false positive (Table S7). Importantly, within the subgroup of TP53 mutant tumors, t-tests failed to identify more genes associated with complete responses than would be expected by chance.
###end p 53
###begin p 54
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b030">30</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b032">32</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b033">33</xref>
###xml 188 196 188 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g002">Figure 2</xref>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 295 375 295 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROM1, cell division cycle 20 homolog [CDC20], CDKN2A, TTK protein kinase [TTK],</italic>
###xml 380 400 380 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">adrenomedullin [ADM]</italic>
###xml 403 411 403 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g002">Figure 2</xref>
###xml 414 422 414 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st007">Table S7</xref>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b014">14</xref>
###xml 644 648 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 688 691 688 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 753 756 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 903 911 903 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st008">Table S8</xref>
###xml 928 931 928 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 924 931 924 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1<sup>pos</sup></italic>
###xml 965 969 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1033 1036 1033 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1079 1083 1079 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1224 1232 1224 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g002">Figure 2</xref>
###xml 1235 1243 1235 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st007">Table S7</xref>
###xml 1257 1261 1257 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 1341 1345 1341 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1473 1476 1473 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 1516 1526 1516 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-sd001">Dataset S1</xref>
###xml 1528 1536 1528 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g003">Figure 3</xref>
Examining the genes associated with TP53 status, we found that, as expected, wild-type TP53 tumors overexpressed many ESR1-associated genes [30,32,33], as well as ribosomal protein genes (Figure 2B). In contrast, TP53 mutant tumors overexpressed, among others, a number of master genes (such as PROM1, cell division cycle 20 homolog [CDC20], CDKN2A, TTK protein kinase [TTK], and adrenomedullin [ADM]) (Figure 2B; Table S7). Most of these mutant TP53 associated genes did not overlap with the ones described in a recent study that used direct TP53 sequencing and a different chip [14]. To exclude the possibility that the genes associated with TP53 mutant status might merely reflect ESR1neg status, we repeated this analysis within the subgroup of ESR1pos tumors. We again found six out of the top ten genes previously identified among 15 top genes differentiating TP53-mutant versus wild-type tumors (Table S8) within the ESR1pos subgroup, demonstrating that the TP53-mutant genes that we have identified do not simply reflect ESR1neg status. In order to validate these mutant TP53-associated genes, we then assessed by quantitative RT-PCR the levels of expression of the first ten genes with the largest fold difference (Figure 2B; Table S7), as well as ESR1. Most of the 12 gene transcripts tested showed significant differences between TP53-mutant or wild-type tumors, not only in the tumor set used to select those genes, but also in the rest of the samples, the ESR1pos subgroup, and the complete population (Dataset S1; Figure 3).
###end p 54
###begin p 55
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 349 357 349 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st009">Table S9</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b026">26</xref>
To characterize the highly chemosensitive tumors that express the KRT5/6 or KRT17 proteins by immunohistochemistry, we performed t-tests based on the Affymetrix data of TP53 mutant tumors and found overexpression of basal cytokeratins and many genes previously identified in myoepithelial cells, consistent with the proposed origin of these tumors (Table S9) [26].
###end p 55
###begin p 56
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 265 274 265 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-sg001">Figure S1</xref>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Lastly, we compared transcript levels to the immunohistochemical detection of ESR1, CDKN2A (p16), PROM1, KRT5, and KRT17 in all samples, which demonstrated very significant differences in mRNA levels between immunohistochemistry (IHC)+ and IHC- tumors (p < 0.001) (Figure S1). In particular, in most of the TP53-mutant and nine out of ten of the basal tumors (defined as KRT5- or KRT17-staining), PROM1 staining was strongly positive in a few cancer cells that could be breast cancer stem cells.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b018">18</xref>
We show that in noninflammatory breast cancers, TP53 mutations are highly predictive of complete responses to a dose-intense neoadjuvant epirubicin-cyclophosphamide chemotherapy regimen. Why did previous studies fail to identify this relationship? We believe that the results reported here reflect the use of a very aggressive DNA-damaging regimen and of a highly efficient technique to determine TP53 status, which detects not only mutations and deletions, but also abnormal splicing events [18]. It is also possible that some previous studies were biased by the presence of inflammatory breast cancers in the study population.
###end p 58
###begin p 59
###xml 3 7 3 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 226 230 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b034">34</xref>
###xml 410 414 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b010">10</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b035">35</xref>
###xml 771 781 771 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21 CDKN1A</italic>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b036">36</xref>
###xml 801 805 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b010">10</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b037">37</xref>
###xml 921 947 921 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Topoisomerase II A (TOP2A)</italic>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b038">38</xref>
###xml 1055 1060 1055 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TOP2A</italic>
###xml 1220 1224 1220 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1343 1348 1343 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Top2A</italic>
###xml 1464 1468 1464 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1533 1537 1533 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1637 1639 1637 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b034">34</xref>
###xml 1713 1717 1713 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1772 1774 1772 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b039">39</xref>
As TP53 is a master gene controlling acute DNA-damage response, its functional integrity was expected to control cell survival, particularly after a dose-dense regimen triggering both double-strand breaks and DNA cross-links. TP53 activation induces a plethora of biological responses (transient cell cycle arrest, senescence, and/or apoptosis) that may have opposing effects on cancer therapy responses [34]. TP53 or CDKN1A deficiencies, which impede chemotherapy-induced cell-cycle arrest, dramatically increase anthracyclin-induced cell death ex vivo [10]. TP53-induced cell-cycle arrest should also protect cells from cyclophosphamide, which, in vivo, only kills rapidly cycling cells [35]. Note that one of the few genes induced by chemotherapy in breast cancers is p21 CDKN1A [36]. In contrast, TP53-mutant cells that cannot arrest in the cell cycle would subsequently progress towards mitotic catastrophe [10,37]. Topoisomerase II A (TOP2A) expression is an important determinant of epirubicin response [38]. When we investigated the expression of TOP2A by RT-PCR in all the samples, no significant differences in transcript levels were observed between responsive and unresponsive tumors, independently of their TP53 status (unpublished data). We suggest that the very high dose of cyclophosphamide used here bypasses the influence of Top2A in controlling response to epirubicin. Whatever the exact mechanism(s) involved, the exquisite chemosensitivity of TP53 mutant breast cancers strongly favors the hypothesis that here, TP53 activation principally blocks cell cycle progression, rather than triggering a cell death program [34]. In line with our observations, transient pharmacological inhibition of TP53 was recently proposed to boost chemotherapy efficacy [39].
###end p 59
###begin p 60
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROM1,</italic>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b040">40</xref>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 527 535 527 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g002">Figure 2</xref>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROM1</italic>
###xml 737 746 737 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g003">Figures 3</xref>
###xml 780 786 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 844 853 844 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-sg001">Figure S1</xref>
###xml 894 898 894 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 985 991 985 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1003 1007 1003 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1113 1115 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b027">27</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b029">29</xref>
###xml 1160 1168 1160 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 1227 1274 1227 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CDKN2A, CKS2, TTK, CDC20, CENPA, CCNB1, CCNB2,</italic>
###xml 1279 1284 1279 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BUB1)</italic>
###xml 1307 1311 1307 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1413 1415 1413 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b041">41</xref>
The expression studies performed here have identified and validated a transcriptional profile associated with mutant TP53 status (and hence indirectly to response), but failed to identify, within the TP53 mutant group, a specific profile associated with complete response. Yet, many of these TP53 mutant-associated genes would be helpful tools in characterizing the pathophysiology of these tumors. PROM1, a marker of normal or cancer stem cells [40], is the gene with the highest fold-difference in TP53-mutant breast tumors (Figure 2B) or several other tumor types (unpublished data). Basal cancers, which were proposed to have a stem cell origin, are virtually all TP53 mutant and express high levels of PROM1 transcript and protein (Figures 3 and S1). Very high expression of CDKN2A transcript was associated with cytoplasmic p16 staining (Figure S1) and was almost exclusively observed in TP53 mutant tumors, consistent with the absence of selection pressure for silencing of the CDKN2A locus when TP53 is mutated. Note that several studies have shown that cytoplasmic p16 was associated with poor survival [27-29], while here it predicts responsiveness (Figure 1A). Finally, a large number of cell-cycle checkpoint genes (CDKN2A, CKS2, TTK, CDC20, CENPA, CCNB1, CCNB2, and BUB1) were overexpressed in TP53-mutant tumors, which may facilitate the execution of mitotic catastrophe upon chemotherapy exposure [41].
###end p 60
###begin p 61
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b013">13</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b014">14</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b016">16</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b030">30</xref>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b003">3</xref>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 572 580 572 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 610 614 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 721 725 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 758 759 758 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 768 776 768 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040090-g001">Figure 1</xref>
###xml 837 841 837 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1086 1090 1086 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1412 1415 1412 1415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1449 1453 1449 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1523 1524 1523 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b007">7</xref>
###xml 1549 1553 1549 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1634 1636 1634 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b042">42</xref>
###xml 1786 1788 1786 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b025">25</xref>
###xml 1789 1791 1789 1791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b026">26</xref>
###xml 1792 1794 1792 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b033">33</xref>
###xml 1795 1797 1795 1797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b043">43</xref>
###xml 1944 1946 1944 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b035">35</xref>
###xml 1947 1949 1947 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b043">43</xref>
###xml 1958 1962 1958 1962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 2171 2173 2171 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b044">44</xref>
###xml 2267 2272 2267 2272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
###xml 2243 2251 <span type="species:ncbi:9606">patients</span>
Several studies have repeatedly demonstrated worse outcomes for patients with TP53-mutant breast tumors when treated with a standard regimen, implying that mutant TP53 is a poor prognostic factor [13,14,16,30]. In our study, mutant TP53 was the major independent predictive factor of complete pathological responses, which itself is the major predictor of long-term survival in patients previously treated with the same protocol [3]. Accordingly, TP53-mutant patients from this study appeared to have a more favorable event-free survival than those with a wild-type TP53 (Figure 1B). However, if patients with TP53-mutant tumors failed to reach a complete response, their survival was significantly worse than those with TP53 wild-type, unresponsive tumors (p = 0.02, Figure 1B), consistent with previous studies. The coexistence, among TP53-mutant tumors, of two very different types of tumors (i.e., the responsive ones with good prognosis and the unresponsive ones with very poor prognosis) may account for the conflicting results of the literature regarding the prognostic value of TP53 status in breast cancer. The apparent paradox between the results of our study and previous ones is likely treatment-related, as the regimen used here had a dose intensity two to four times higher than most others, with only two-week intervals between courses. However, some recent studies are in line with our data: ESR1neg breast cancers (which are mostly TP53 mutant) were found to be more sensitive to neoadjuvant chemotherapy [7] and, in a pilot study, TP53 staining was associated with favorable responses to preoperative anthracyclins [42]. Despite the small number of cases analyzed, our data also suggest that basal cancers, described as having a dismal prognosis in all other studies [25,26,33,43], are exquisitely sensitive to this association, possibly because of their rapid proliferation, which favors cyclophosphamide-induced cell death [35,43]. Thus, TP53-mutant tumors may have a poor outcome when treated with conventionally dosed chemotherapies, but may be highly responsive to dose intensification. Hence, in the neoadjuvant, or even in the adjuvant settings [44], this type of dose-intense regimen could be particularly suited for patients with basal and TP53-mutant tumors.
###end p 61
###begin title 62
Supporting Information
###end title 62
###begin title 63
Translation of the Abstract into Arabic by A. Bazarbachi
###end title 63
###begin p 64
Click here for additional data file.
###end p 64
###begin title 65
Translation of the Abstract into Chinese by B. Chen and J. Zhu
###end title 65
###begin p 66
Click here for additional data file.
###end p 66
###begin title 67
Translation of the Abstract into French by P. Bertheau and H. de The
###end title 67
###begin p 68
Click here for additional data file.
###end p 68
###begin title 69
Translation of the Abstract into German by N. Schwartz and J. Lehmann-Che
###end title 69
###begin p 70
Click here for additional data file.
###end p 70
###begin title 71
Translation of the Abstract into Japanese by H. Murata and Y. Takahashi
###end title 71
###begin p 72
Click here for additional data file.
###end p 72
###begin title 73
Translation of the Abstract into Portuguese by J. Pedroso de Oliveira
###end title 73
###begin p 74
Click here for additional data file.
###end p 74
###begin title 75
Translation of the Abstract into Romanian by M. Varna
###end title 75
###begin p 76
Click here for additional data file.
###end p 76
###begin title 77
Translation of the Abstract into Spanish by H. Pisonero and P. Santa Olalla
###end title 77
###begin p 78
Click here for additional data file.
###end p 78
###begin title 79
Supplementary Statistical Data
###end title 79
###begin p 80
(290 KB PDF)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin title 82
Protein Validation Studies
###end title 82
###begin p 83
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Left: example of tumors scored positive or negative by immunohistochemistry. Right: mean RNA levels for tumors positive and negative for ESR1, KRT5, KRT17, PROM1, and CDKN2A (p16). Pos, positive; neg, negative; cyt, cytoplasmic; nuc, nuclear; ***, p < 0.001 when comparing the levels of mRNA between IHC+ and IHC- tumors. Bars indicate 50 mum.
###end p 83
###begin p 84
(1.1 MB PDF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin title 86
###xml 19 27 <span type="species:ncbi:9606">Patients</span>
Characteristics of Patients and Tumors
###end title 86
###begin p 87
Sets: S1, single amplification for microarray; S2, double amplification for microarray; S3, tumors not analyzed by microarray, but used for RT-PCR and/or immunohistochemical studies. The raw data for quantitative RT-PCR analysis (ddCT) or other immunohistochemical tests are highlighted in yellow. C, complete; DOD, died of disease; EC, epirubicin/cyclophosphamide; ET, epirubicin/docetaxel; KRT, cytokeratin; NA, not applicable; NC, not complete; nd, not done; wd, without disease; META, metastatic; METADiag, metastatic at diagnosis; TNM, tumor, node, metastasis.
###end p 87
###begin p 88
(52 KB PDF)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin title 90
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 48 56 <span type="species:ncbi:9606">Patients</span>
Summary of the Data on the 28 TP53 Mutations in Patients Studied for Pathological Response to Chemotherapy
###end title 90
###begin p 91
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b023">23</xref>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040090-b024">24</xref>
###xml 50 55 <span type="species:ncbi:4932">yeast</span>
FASAY, functional analysis of separated allele in yeast [23,24] codon 72; R, arginine; P, proline.
###end p 91
###begin p 92
(28 KB PDF)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin title 94
###xml 19 26 <span type="species:ncbi:9606">Patient</span>
Genes Specific for Patient Cluster 1
###end title 94
###begin p 95
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Probe set, ratios of mean values, p-values, gene symbol, and gene name are indicated. Class specific gene lists were generated by the intersection of all group-wise t-tests with an F-test of all three classes (i.e., C1-specific genes, intersection of C1 versus C2, C1 versus C3 and F test, etc.).
###end p 95
###begin p 96
(68 KB PDF)
###end p 96
###begin p 97
Click here for additional data file.
###end p 97
###begin title 98
###xml 19 26 <span type="species:ncbi:9606">Patient</span>
Genes Specific for Patient Cluster 2
###end title 98
###begin p 99
###xml 27 35 27 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st003">Table S3</xref>
For details, see legend of Table S3.
###end p 99
###begin p 100
(86 KB PDF)
###end p 100
###begin p 101
Click here for additional data file.
###end p 101
###begin title 102
###xml 19 26 <span type="species:ncbi:9606">Patient</span>
Genes Specific for Patient Cluster 3
###end title 102
###begin p 103
###xml 27 35 27 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st003">Table S3</xref>
For details, see legend of Table S3.
###end p 103
###begin p 104
(59 KB PDF)
###end p 104
###begin p 105
Click here for additional data file.
###end p 105
###begin title 106
List of the 77 Probe Sets That Are Differentially Expressed between Tumors That Exhibited a Complete Response to Chemotherapy and Those That Did Not
###end title 106
###begin p 107
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Probe sets associated with TP53 status are indicated. The false discovery rate in this experiment is 26%.
###end p 107
###begin p 108
(26 KB PDF)
###end p 108
###begin p 109
Click here for additional data file.
###end p 109
###begin title 110
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
List of the Probe Sets with the Highest Differential Expression in TP53-Mutant Versus TP53 Wild-Type Tumors
###end title 110
###begin p 111
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Fold ratio and p-values are indicated. A total of 1,599 significant genes were identified.
###end p 111
###begin p 112
(46 KB PDF)
###end p 112
###begin p 113
Click here for additional data file.
###end p 113
###begin title 114
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 77 80 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
List of Probe Sets Associated with TP53 Mutant Status in the Subgroup of ESR1pos Tumors
###end title 114
###begin p 115
###xml 138 146 138 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st007">Table S7</xref>
###xml 170 178 170 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st007">Table S7</xref>
Note that several of the top genes (when ordered by decreasing fold-change values) were previously identified in the complete population (Table S7). Genes in common with Table S7 are highlighted.
###end p 115
###begin p 116
(31 KB PDF)
###end p 116
###begin p 117
Click here for additional data file.
###end p 117
###begin title 118
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Genes Identified by t-Tests of TP53-Mutant KRT5/6pos or KRT17pos Tumors Versus KRT5/6 neg and KRT17neg Tumors
###end title 118
###begin p 119
(42 KB PDF)
###end p 119
###begin p 120
Click here for additional data file.
###end p 120
###begin title 121
Accession Numbers
###end title 121
###begin p 122
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PROM1</italic>
###xml 316 321 316 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TMSNB</italic>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT7</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RIS1</italic>
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHLDA2</italic>
###xml 434 438 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAFF</italic>
###xml 463 466 463 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADM</italic>
###xml 491 494 491 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TTK</italic>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDC20</italic>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ESR1</italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT5</italic>
###xml 705 709 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT6</italic>
###xml 734 739 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT17</italic>
###xml 764 769 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TOP2A</italic>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PUMA</italic>
###xml 826 829 826 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAX</italic>
###xml 854 858 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BUB1</italic>
###xml 911 916 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNB2</italic>
###xml 941 947 941 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 972 977 972 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCNB1</italic>
###xml 1002 1007 1002 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CENPA</italic>
###xml 1036 1040 1036 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CKS2</italic>
The primary data for the microarrays were deposited at the European Bioinformatics Institute (EBI) Web site () (ArrayExpress number E-TABM-43). Accession numbers for the genes and corresponding proteins cited in the main text are given below in PubMed format (gene, NM_; protein, NP_): PROM1 (NM_006017, NP_006008); TMSNB (NM_021992, NP068832); KRT7 (NM_005556, NP_005547); RIS1 (NM_057212, NP_476560); PHLDA2 (NM_003311, NP_003302); MAFF (NM_010755, NP_034885); ADM (NM_001124, NP_001115); TTK (NM_003318, NP_003309); CDC20 (NM_001255, NP_001246); CDKN2A (NM_000077, NP_000068); CDKN2A (NM_058195, NP_478102); ESR1 (NM_000125, NP_000116); ERBB2 (NM_001005862, NP_001005862); KRT5 (NM_000424, NP_000415); KRT6 (NM_080747, NP_542785); KRT17 (NM_000422, NP_000413); TOP2A (NM_001067, NP_001058.2); PUMA (NM_014417 , NP_055232); BAX (NM_138763, NP_620118); TP53 (NM_000546,NP_006133); BUB1 (NM_004336, NP_000380); CCNB2 (NM_004701, NP_004692); CDKN1A (NM_000389, NP_000380); CCNB1 (NM_031966, NP_114172); CENPA (NM_001809, NP_001800); and CKS2 (NM_001827, NP_001818.1).
###end p 122
###begin p 123
###xml 377 385 <span type="species:ncbi:9606">patients</span>
This work was first presented in September 2004 at the University of California San Francisco Comprehensive Cancer Center. We thank all of the technicians at the Saint Louis hospital Pathology Laboratory, the technicians at the Biochemistry Department (Evelyne Witmer, Dominique Cuvillier, Dominique Chapelin, and Martine Legrand), and the clinical ward staff who referred the patients. We also thank Bernard Asselain and Sylvie Chevret for expert statistical advice and Fabien Petel for help with formatting the data to be Minimum Information About a Microarray Experiment (MIAME)-compliant. We thank all of our colleagues for critical reading of and constructive comments on the manuscript, in particular G. Kroemer, F. Sigaux, O. Delattre, M. H. Stern, E. Cvitkovic, and J. Zucman. Microarrays were performed at the Institut de Genetique et de Biologie Moleculaire et Cellulaire () by C. Thibault.
###end p 123
###begin p 124
This work is dedicated to the memory of Claude Savelli who was lost to breast cancer at a young age.
###end p 124
###begin title 125
References
###end title 125
###begin article-title 126
The best use of chemotherapy in the adjuvant setting
###end article-title 126
###begin article-title 127
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
###end article-title 127
###begin article-title 128
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer
###end article-title 128
###begin article-title 129
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
###end article-title 129
###begin article-title 130
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations
###end article-title 130
###begin article-title 131
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
###end article-title 131
###begin article-title 132
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
###end article-title 132
###begin article-title 133
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance
###end article-title 133
###begin article-title 134
Intrinsic tumour suppression
###end article-title 134
###begin article-title 135
###xml 21 26 <span type="species:ncbi:9606">human</span>
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
###end article-title 135
###begin article-title 136
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
###end article-title 136
###begin article-title 137
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
###end article-title 137
###begin article-title 138
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
###end article-title 138
###begin article-title 139
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
###end article-title 139
###begin article-title 140
###xml 106 114 <span type="species:ncbi:9606">patients</span>
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients
###end article-title 140
###begin article-title 141
###xml 59 67 <span type="species:ncbi:9606">patients</span>
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
###end article-title 141
###begin article-title 142
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
###end article-title 142
###begin article-title 143
###xml 106 111 <span type="species:ncbi:4932">yeast</span>
Prognostic significance of p53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay
###end article-title 143
###begin article-title 144
###xml 124 132 <span type="species:ncbi:9606">patients</span>
High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients
###end article-title 144
###begin article-title 145
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
###end article-title 145
###begin article-title 146
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
###end article-title 146
###begin article-title 147
A simple p53 functional assay for screening cell lines, blood, and tumors
###end article-title 147
###begin article-title 148
Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract
###end article-title 148
###begin article-title 149
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
###end article-title 149
###begin article-title 150
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
###end article-title 150
###begin article-title 151
###xml 82 90 <span type="species:ncbi:9606">patients</span>
P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy
###end article-title 151
###begin article-title 152
Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype
###end article-title 152
###begin article-title 153
Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation
###end article-title 153
###begin article-title 154
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
###end article-title 154
###begin article-title 155
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
###end article-title 155
###begin article-title 156
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 156
###begin article-title 157
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
###end article-title 157
###begin article-title 158
p53 and cancer therapy: A double-edged sword
###end article-title 158
###begin article-title 159
Factors determining cell killing by chemotherapeutic agents in vivo-II. Melphalan, chlorambucil and nitrogen mustard
###end article-title 159
###begin article-title 160
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease
###end article-title 160
###begin article-title 161
Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents
###end article-title 161
###begin article-title 162
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401
###end article-title 162
###begin article-title 163
Cancer biology: Can less be more for p53?
###end article-title 163
###begin article-title 164
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumour initiating cells
###end article-title 164
###begin article-title 165
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death
###end article-title 165
###begin article-title 166
Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: The predictive role of p53 expression
###end article-title 166
###begin article-title 167
Basal-like breast carcinomas: Clinical outcome and response to chemotherapy
###end article-title 167
###begin article-title 168
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
###end article-title 168
###begin title 169
Figures and Tables
###end title 169
###begin title 170
Response to Chemotherapy
###end title 170
###begin p 171
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 439 440 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
(A) Top: distribution of the pathological response to chemotherapy of the 80 patients according to TP53 status as well as other clinical or biological annotations. T, T stage from the TNM classification. p-Values are below each contingency table. Bottom: results from adjusted Chi2 tests. The variables tested for the prediction of complete response are shown in the columns; the stratification variable is listed in the first column. The p-values are color coded (dark yellow and bold type, p < 0.0001; light yellow, 0.0001 < p < 0.01).
###end p 171
###begin p 172
###xml 186 194 186 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 169 176 <span type="species:ncbi:9606">patient</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
(B) Left graph: Kaplan-Meier analysis of the event-free survival of the patients without metastatic extension at diagnosis, all treated with the same regimen (including patient P80, see Table S1). Note that all five relapses in the TP53 mutant group occurred in the first 18 months, while in the TP53 wild-type group, relapses were still observed when survival of many patients was censored. Right graph: overall survival stratified by TP53 status and complete response.
###end p 172
###begin title 173
Microarray Data
###end title 173
###begin p 174
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 701 709 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040090-st001">Table S1</xref>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
###xml 677 684 <span type="species:ncbi:9606">patient</span>
(A) Hierarchical clustering based on the 990 most varying genes in 37 tumors with Affymetrix-grade RNA. C1, C2, and C3 denote the three tumor clusters. Annotations: TP53 status (red, mutant; yellow, wild-type); ESR1 (immunohistochemistry) (blue, positive; green, negative); basal cytokeratins (KRT5/6 or 17, immunohistochemistry) (orange, positive; gray, negative); ERBB2 (RT-PCR) (pink, positive; gray, negative); complete pathological response to chemotherapy (blue, complete; red, incomplete); and tumor grade (green, grade 3; purple, grade 1 or 2). For chemotherapy response, patients treated with other regimens are indicated by a question mark. P1, P2, etc. refer to the patient's references in Table S1.
###end p 174
###begin p 175
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
(B) Genes linked to TP53 status (t-tests): the top and bottom genes (classified by fold changes [FC]) are shown.
###end p 175
###begin title 176
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Validation of Mutant TP53 Profile in Breast Cancers
###end title 176
###begin p 177
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 319 323 319 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 453 454 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
For each of the 12 most varying genes (11 overexpressed and one underexpressed), four box plots are shown, representing the distribution of the ddCt values for the four following groups of samples: (i) TP53 mutant from the training set (empty red box), (ii) TP53 wild type from the training set (empty blue box), (iii) TP53 mutant from the validation set (filled red box), and (iv) TP53 wild type from the validation set (filled blue box). *p < 0.05; **p < 0.01, ***p < 0.001 (t-tests). Small circles indicate outliers.
###end p 177
###begin p 178
###xml 22 30 <span type="species:ncbi:9606">Patients</span>
Description of the 80 Patients Analyzed for Chemotherapy Response
###end p 178
###begin p 179
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 179
###begin p 180
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
Author contributions. P. Bertheau, E. Turpin, D.S. Rickman, A. de Reynies, J.-P. Feugas, H. Soliman and H. de The analyzed the data. H. de The designed the study. M. Espie, M. Marty and J.-L. Misset enrolled patients. P. Bertheau, E. Turpin, D.S. Rickman, A. de Reynies, M. Espie, J. Lehmann-Che and H. de The contributed to writing the paper. P. Bertheau, E. Turpin, M. Espie, L.-F. Plassa, H. Soliman, M. Varna, A. de Roquancourt, J. Lehman-Che, M. Marty, and J.-L. Misset collected data and/or did experiments for the study. D. Rickman and A. de Reynies performed the statistical analyses of all the data. A. de Reynies created analytical tools used for the analysis. A. Janin organized procedures to obtain biopsies and tumor samples under optimal conditions for molecular analyses.
###end p 180
###begin p 181
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported by Programme Hospitalier de Recherche Clinique (PHRC), Carte d'identite des tumeurs (CIT) program founded by the Ligue Nationale Contre le Cancer, the Barletta Foundation and Association pour la Recherche sur le Cancer (ARC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 181

